Aristolochic acid C, a metabolite of carcinogenic aristolochic acids (AAs). is a carcinogen found in aristolochia debilis. It can inhibit PLA2.

Lp-PLA2 -IN-1 inhibits Lp-PLA2 activity, and can used in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

m-3M3FBS is a novel phospholipase C activator. It can be developed as a novel anti-leukemic agent.

ML 349 is a selective and reversible lysophospholipase 2 (LYPLA2) inhibitor with IC50 of 144 nM.

CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM.

D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM) and antiviral and antitumor agent.

Darapladib is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM.

Varespladib is a potent and selective human non-pancreatic secretory phospholipase A2 (sPLA) inhibitor with IC50 of 7 nM.